Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersEditorials
You have accessRestricted Access

Cytomegalovirus and Anemia: Not Just for Transplant Anymore

Michael E. Seifert and Daniel C. Brennan
JASN August 2014, 25 (8) 1613-1615; DOI: https://doi.org/10.1681/ASN.2014030249
Michael E. Seifert
*Division of Pediatric Nephrology, Southern Illinois University School of Medicine, Springfield, Illinois; and
†Division of Pediatric Nephrology, Department of Pediatrics, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel C. Brennan
‡Renal Division, Department of Medicine, Washington University at St. Louis, St. Louis, Missouri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • cytomegalovirus
  • CKD
  • anemia

Cytomegalovirus (CMV) is one of the most important viruses in renal transplantation that causes significant morbidity and mortality, even in the current era of effective prophylaxis and treatment. The CMV syndrome is characterized by fever, malaise, and transplant dysfunction that manifests as AKI, leukopenia, monocytosis, and anemia. Less than 20 years ago, in the absence of effective prophylactic or treatment agents, immunosuppression reduction was the only treatment and was commonly associated with death and/or transplant failure. The introduction of effective antiviral medications, such as ganciclovir and valganciclovir, has significantly reduced the mortality directly attributable to CMV infection. However, despite this reduction in mortality, the indirect effects of CMV infection are still relatively common. CMV DNA has been detected in kidney transplants with chronic allograft nephropathy and subclinical CMV viremia has been associated with poor long-term transplant outcomes.1–4 In this issue of JASN, the article by Butler et al. highlights anemia as another indirect effect of CMV infection and reminds us of associations between CMV, anemia, and native CKD, of which many clinicians may not be aware.5 Butler et al. performed an exceptional translational study that began with two clinical observations that are well known to nephrologists. First, patients with native CKD demonstrate a direct correlation between the loss of kidney function, declining erythropoietin (EPO) levels, and worsening anemia. Second, kidney transplant recipients demonstrate a direct association between CMV and post-transplant anemia. The investigators sought to elucidate the mechanism of declining EPO production in CMV-affected patients with native and transplant CKD.

Anemia is an important complication of native and transplant CKD that results from loss of endogenous EPO production from the diseased kidney. It affects 70%–90% of patients with stages 4 and 5 CKD and 40%–50% of kidney transplant recipients within the first 6 months after transplantation.6,7 The findings in transplant recipients are particularly troubling because EPO deficiency and anemia occur in those individuals with normal estimated transplant function as well as decreased kidney function, highlighting the existence of additional contributors to anemia in kidney disease beyond the loss of renal function. Anemia is an important risk factor for the immense morbidity and mortality associated with CKD, including reduced exercise tolerance, left ventricular hypertrophy, and left ventricular systolic dysfunction.8–10 Patients with CKD-associated anemia experience increased hospitalization rates and length of stay in addition to higher mortality rates. Partial correction of CKD-associated anemia with recombinant EPO has improved many of these comorbidities, but there are many patients for whom recombinant EPO is ineffective. The precise mechanism of declining EPO production in native and transplant CKD and the resistance to treatment with recombinant EPO in select patients remain poorly understood. The exciting work of Butler et al. partially addresses this gap in knowledge.5

CMV targets renal glomerular, vascular, epithelial, interstitial, and tubular cells, including fibroblast-type cells in the renal cortex that activate EPO production in the setting of local tissue hypoxia. CMV DNA can be detected in asymptomatic kidney transplant recipients and its presence has been associated with severe anemia within the first 6 months after transplantation.1,11 Although there are no studies to date of CMV DNA in native kidneys with CKD, there are numerous reports of systemic CMV infection or reactivation in patients with CKD. Furthermore, patients with native CKD who are CMV-IgG positive require higher erythrocyte stimulating agent doses to treat anemia than patients who are CMV negative.12 However, a direct mechanism to explain the apparent association between CMV and anemia had remained a mystery.

The authors previously found CMV DNA in kidney transplants with chronic allograft nephropathy at the time of nephrectomy.1 They examined whether patients with native CKD also had CMV DNA in their kidneys even in the absence of overt CMV disease. Through carefully designed and conducted translational studies, they explored whether the presence of CMV DNA in these kidneys correlated with CMV serostatus, and if so, by what mechanism would CMV affect EPO production. The investigators effectively used human specimens and animal and cellular models to answer these questions and translate their mechanistic findings back toward the bedside. In brief, Butler et al. found that 9 of 13 (69%) kidney biopsies from patients with native stage 4 CKD tested positive for CMV-immediate early (IE) proteins despite the absence of signs or symptoms attributable to CMV infection. Importantly, although only two patients were CMV seronegative, their kidney biopsies were also negative for CMV-IE proteins. CMV serostatus was then examined in the context of hematologic data from these 13 patients. CMV-IgG levels were inversely correlated with both hemoglobin and red blood cell counts. These important findings confirm the prevalence of subclinical CMV infection in a small cohort of humans with CKD and demonstrate an association between CMV seropositivity and anemia that the authors studied further in animal and cellular models.

Next, the investigators infected BALB/c mice with murine CMV and followed them prospectively over 6 weeks. EPO levels were lower at 1 and 6 weeks in CMV-infected mice compared with uninfected controls. Unlike the human CKD cohort, hemoglobin and red blood cell counts were not affected by murine CMV infection, although the mean corpuscular hemoglobin concentration was significantly lower in the CMV-infected group. One possible explanation for these divergent findings is that in humans, CKD-associated anemia often takes weeks or months to develop after a decline in EPO levels because the t1/2 of erythrocytes is 90–120 days.13 Therefore, if the CMV-infected mice had a longer follow-up period, the decline in EPO levels may have eventually produced the declines in hemoglobin and erythrocyte counts that were seen in humans with CKD. As discussed by the authors, another possibility is that the murine CMV infection was controlled by 6 weeks because EPO levels had returned to baseline by that time. The transient drop in EPO levels may have been inadequate to produce significant anemia, given the long t1/2 of existing erythrocytes.

In the cell-based models using cultured human EPO-producing cells (HEPCs), CMV inoculation resulted in increased expression of CMV-IE proteins, which were detected in kidney biopsies of native CKD patients who were CMV seropositive. When exposed to hypoxia, CMV-infected HEPCs produced significantly less EPO mRNA than control cells. Constitutive EPO production under normoxic conditions was not affected by CMV infection, which suggests a direct effect of CMV infection on the response of HEPCs to hypoxia. To show that the diminished EPO effect was not a general viral phenomenon, the investigators showed that HEPCs infected with Kaposi’s sarcoma virus had normal EPO production under normoxic conditions and increased EPO mRNA production under hypoxic conditions, in contrast with the effects of CMV in this cell line. Further studies showed that it was the CMV-IE gene expression (identical to CMV-IE proteins detected in CMV-infected HEPCs and human kidneys with CKD) that directly mediated the lowering of the EPO mRNA. In a clinically relevant cellular study, treatment of the cells with valganciclovir, an inhibitor of CMV-late gene expression, had no effect on EPO mRNA production and supported that IE or early CMV gene expression was required to reduce EPO production. In several additional elegant experiments, the investigators showed that CMV infection reduces EPO mRNA production by inhibiting the expression of hypoxia-induced transcription factor-2α and that there was a dose response with CMV-IE gene expression. The working model shown in Figure 8 by Butler et al. is a brilliant figure synthesizing this novel mechanistic work.

A major strength of this study is the authors’ use of clinical observations, human biospecimens, animal models, and cell culture experiments to conduct true translational research that addresses an important question for clinicians. The finding of CMV-IE proteins in kidneys from humans with CKD but no overt symptoms of the CMV syndrome is important but must be confirmed in larger prospective studies. These should include studies of immunosuppressed and nonimmunosuppressed patients with native CKD, as well as the effect of CMV on resistance to recombinant EPO therapy. An intriguing extension of this mechanistic study would include a treatment arm to determine the effect of antiviral medications that target CMV on CKD-associated anemia. We applaud this innovative study that has the potential for broad applications in transplantation but more importantly in native CKD, which currently affects >20 million people in the United States.

Disclosures

None.

Acknowledgments

M.E.S. is supported by grants from the National Institutes of Health National Center for Advancing Translational Sciences (KL2-RR024994 and UL1-RR024992) and the National Institute of Diabetes and Digestive and Kidney Diseases (L40-DK099748-01). M.E.S. is also supported by a Clinician Scientist Award from Southern Illinois University.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related article, “Human Cytomegalovirus Inhibits Erythropoietin Production,” on pages 1669–1678.

  • Copyright © 2014 by the American Society of Nephrology

References

  1. 1.↵
    1. Dzabic M,
    2. Rahbar A,
    3. Yaiw KC,
    4. Naghibi M,
    5. Religa P,
    6. Fellström B,
    7. Larsson E,
    8. Söderberg-Nauclér C
    : Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 53: 969–976, 2011
    OpenUrlCrossRefPubMed
  2. 2.
    1. Schnitzler M
    : Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3: 1318, author reply 1319, 2003
    OpenUrlCrossRefPubMed
  3. 3.
    1. Sagedal S,
    2. Hartmann A,
    3. Nordal KP,
    4. Osnes K,
    5. Leivestad T,
    6. Foss A,
    7. Degré M,
    8. Fauchald P,
    9. Rollag H
    : Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66: 329–337, 2004
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Smith JM,
    2. Corey L,
    3. Bittner R,
    4. Finn LS,
    5. Healey PJ,
    6. Davis CL,
    7. McDonald RA
    : Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 21: 1579–1586, 2010
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Butler L,
    2. Dzabic M,
    3. Bakker F,
    4. Davoudi B,
    5. Jeffery H,
    6. Religa P,
    7. Bojakowski K,
    8. Yaiw KC,
    9. Rahbar A,
    10. Soderberg-Naucler C
    : Human cytomegalovirus inhibits erythropoietin production. J Am Soc Nephrol 25: 1669–1678, 2014
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Vanrenterghem Y
    : Anaemia after renal transplantation. Nephrol Dial Transplant 19[Suppl 5]: V54–V58, 2004
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Kazmi WH,
    2. Kausz AT,
    3. Khan S,
    4. Abichandani R,
    5. Ruthazer R,
    6. Obrador GT,
    7. Pereira BJ
    : Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 38: 803–812, 2001
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Xia H,
    2. Ebben J,
    3. Ma JZ,
    4. Collins AJ
    : Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10: 1309–1316, 1999
    OpenUrlAbstract/FREE Full Text
  9. 9.
    1. Ma JZ,
    2. Ebben J,
    3. Xia H,
    4. Collins AJ
    : Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610–619, 1999
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Levin A,
    2. Thompson CR,
    3. Ethier J,
    4. Carlisle EJ,
    5. Tobe S,
    6. Mendelssohn D,
    7. Burgess E,
    8. Jindal K,
    9. Barrett B,
    10. Singer J,
    11. Djurdjev O
    : Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34: 125–134, 1999
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Einollahi B,
    2. Lessan-Pezeshki M,
    3. Rostami Z,
    4. Kalantar E,
    5. Afshar R,
    6. Beiraghdar F
    : Anemia after kidney transplantation in adult recipients: prevalence and risk factors. Transplant Proc 43: 578–580, 2011
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Betjes MG,
    2. Weimar W,
    3. Litjens NH
    : CMV seropositivity determines epoetin dose and hemoglobin levels in patients with CKD. J Am Soc Nephrol 20: 2661–2666, 2009
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Ly J,
    2. Marticorena R,
    3. Donnelly S
    : Red blood cell survival in chronic renal failure. Am J Kidney Dis 44: 715–719, 2004
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 25 (8)
Journal of the American Society of Nephrology
Vol. 25, Issue 8
August 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Cytomegalovirus and Anemia: Not Just for Transplant Anymore
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cytomegalovirus and Anemia: Not Just for Transplant Anymore
Michael E. Seifert, Daniel C. Brennan
JASN Aug 2014, 25 (8) 1613-1615; DOI: 10.1681/ASN.2014030249

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Cytomegalovirus and Anemia: Not Just for Transplant Anymore
Michael E. Seifert, Daniel C. Brennan
JASN Aug 2014, 25 (8) 1613-1615; DOI: 10.1681/ASN.2014030249
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • QALYs, DALYs and Now PALYs: Strengthening the Argument for Prevention of CKD
  • Management of Obesity in Adults with CKD
  • Me Or Your Own Eyes: RNA-Seq and the Kidney
Show more Up Front Matters

Editorials

  • Could NAD+ Precursor Supplements Induce a Legacy of Protection against Diabetic Nephropathy?
  • Race and the Estimation of GFR: Getting it Right
  • Monkeying about with Nephron Formation
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Human Cytomegalovirus Inhibits Erythropoietin Production
  • PubMed
  • Google Scholar

Keywords

  • cytomegalovirus
  • CKD
  • anemia

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire